Approval · Notice of Compliance 31615 · 2023
FLUZONE QUADRIVALENT: Notice of Compliance 31615
Issued September 13, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31615
- Date
- September 13, 2023
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Annual update ¿ strain changes
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLUZONE QUADRIVALENT | Not yet assigned | — |
| FLUZONE® HIGH-DOSE QUADRIVALENT | Not yet assigned | — |
Medicinal ingredients
- HAEMAGGLUTININ-STRAIN A(H1N1) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN A(H3N2) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN B(VICTORIA) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN B(YAMAGATA) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN A(H1N1) 60 MCG per 0.7ML
- HAEMAGGLUTININ-STRAIN A(H3N2) 60 MCG per 0.7ML
- HAEMAGGLUTININ-STRAIN B(VICTORIA) 60 MCG per 0.7ML
- HAEMAGGLUTININ-STRAIN B(YAMAGATA) 60 MCG per 0.7ML